ArticleAbdominal radiology (New York)2026
Diagnostic performance of ultrasound-derived fat fraction for detecting hepatic steatosis in patients with tumor-related liver disease.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate assessment of hepatic steatosis is crucial for preoperative risk stratification in patients with liver tumors. However, the diagnostic performance of the noninvasive ultrasound-derived fat fraction (UDFF) remains uncertain, where tissue heterogeneity can impair measurement reliability. Using histopathology as the reference standard, this study aimed to evaluate the ability of UDFF to detect and grade background hepatic steatosis.
methodsIn this prospective study, 64 adults scheduled for hepatic surgery were enrolled. All patients underwent preoperative UDFF assessment, and postoperative histopathology of non-tumorous liver tissue served as the reference. Diagnostic performance, incremental predictive value, and clinical utility were evaluated using ROC analysis (Youden index for cutoff determination), multivariable regression (ΔAUC assessment), and decision curve analysis.
resultsUDFF values increased progressively with histological steatosis grades (p < 0.0001). The AUCs for detecting S ≥ 1 and S ≥ 2 steatosis were 0.885 and 0.967, with corresponding optimal cutoffs of 4.75% and 8.50%. UDFF was an independent predictor of steatosis (OR = 1.95 for S ≥ 1; OR = 2.58 for S ≥ 2) and significantly improved model discrimination (ΔAUC = 0.161 and 0.256). Decision curve analysis demonstrated a consistent net clinical benefit across clinically relevant threshold probabilities.
conclusionUDFF provides accurate, independent, and clinically meaningful quantification of hepatic steatosis in tumor-related liver disease, and the population-specific cutoff values identified in this study may support improved preoperative evaluation and treatment planning.
Indexed as
Identifiers
42684475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.